Orchid Pharma’s antibiotic invention, ‘Exblifeb,’ which incorporates Enmetazobactam, a beta lactamase inhibitor, has received the European Medicines Agency’s (EMA) recommendation for marketing authorisation.
Designed to address anti-microbial resistance (AMR), ‘Exblifeb’ demonstrates efficacy in treating complicated urinary tract infections (cUTI), pneumonia, and bacteremia caused by extended spectrum beta-lactamase producing pathogens. The company informed that during clinical trials, ‘Exblifeb’ exhibited superior performance compared to the current go-to drug, Piperacillin + Tazobactam. It is positioned as a potent, cost-effective, and Carbapenem-sparing therapy, offering a viable solution in the fight against rising AMR.
Enmetazobactam was invented in India by Orchid and then out-licensed to Allecra Therapeutics for further development.